Companies › Crescent Biopharma
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CR-002 | – | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Oct 2028 |
| CR-001 | – | Phase 1 | Locally Advanced / Metastatic Solid Tumors | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07909031 | CR-002 | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Oncology | Oct 2028 |
| NCT07335497 | CR-001 | Phase 1 | Locally Advanced / Metastatic Solid Tumors | Oncology | Feb 2029 |
Cash of $172m on 2026-06-30; operating cash outflow about $58m a year; runway about 36 months at that burn, to Jun 2029
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.